Association of Type 2 diabetes remission with mortality and vascular outcomes: a systematic review and meta-analysis of longitudinal studies
In brief
Diabetes remission links to 32% fewer cardiovascular events, but not proven to cause benefit
In a review of longitudinal studies, people with type 2 diabetes remission had a 32% lower pooled hazard of cardiovascular events than those without remission. Associations with fewer microvascular and broader vascular complications were less certain, and mortality was not significantly lower; the observational evidence cannot show remission caused better outcomes, so monitoring and risk-factor care should continue.
- Journal
- Diabetology & metabolic syndrome (Q1)
- Published
- 22 October 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Hao Bai, Lingqiao Song, Yating Zhan, Li Dai, Qian He, Jiaxin Duan, et al.
- PMID
- 43015902
- DOI
- 10.1186/s13098-026-02314-w
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 14 November 2026): Summarizes vascular and mortality outcomes after type 2 diabetes remission
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) remission is increasingly recognized as an achievable clinical state. However, its long-term associations with mortality and vascular complications remain uncertain. We conducted a systematic review and meta-analysis of longitudinal studies to evaluate the associations of T2DM remission with all-cause mortality, cardiovascular events, microvascular complications, and macrovascular complications. METHODS: PubMed, Embase, Web of Science, and Scopus were searched from inception to July 20, 2026, without language restrictions. Longitudinal studies were eligible if they included adults with T2DM, assessed remission before outcome ascertainment, compared participants who achieved remission with those who did not achieve or maintain remission, and reported an adjusted effect estimate after at least 12 months of follow-up. Methodological quality was assessed using the Newcastle-Ottawa Scale. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using random-effects models. The certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Ten studies met the eligibility criteria, of which nine contributed to the quantitative synthesis. T2DM remission was not significantly associated with all-cause mortality (3 studies; HR, 0.80; 95% CI, 0.53-1.21; I² = 65.0%), but pooled estimates suggested lower hazards of cardiovascular events (5 studies; HR, 0.68; 95% CI, 0.59-0.80; I² = 11.7%) and microvascular complications (5 studies; HR, 0.60; 95% CI, 0.38-0.93; I² = 93.4%). In an exploratory analysis of broader macrovascular complications, the pooled estimate also suggested a lower hazard (6 studies; HR, 0.74; 95% CI, 0.58-0.93; I² = 75.6%), although substantial heterogeneity was observed. Sensitivity analyses did not materially alter the overall direction of the pooled estimates. The certainty of evidence was low for cardiovascular events and very low for all-cause mortality, microvascular complications, and macrovascular complications. CONCLUSIONS: T2DM remission was associated with lower pooled hazards of cardiovascular events, while the associations with microvascular and macrovascular complications were less certain due to substantial heterogeneity and limited precision. The association between T2DM remission and all-cause mortality remained uncertain. These findings suggest a favorable long-term prognostic association of T2DM remission, although they should not be interpreted as evidence of causality. Long-term glycemic monitoring, comprehensive risk-factor management, and surveillance for diabetes-related complications should therefore continue after remission.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.